title: A novel antiviral strategy for HIV infection.
abstract: The replication of human immunodeficiency virus (HIV) may be modulated in part by host factors such as DNA methylation. Hypermethylation of the HIV provirus may suppress viral replication and play a role in the establishment of latency. HIV seropositive individuals have decreased levels of metabolites involved in methylation. It is proposed that metabolites such as S-adenosylmethionine (SAM), methylcobalamin and methyltetrahydrofolate be explored as potential therapeutic agents in HIV infected individuals.
authors.forename: B A
authors.initials: BA
authors.lastname: May
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000378:metabolism; D004279:DNA, Viral / Q000378:metabolism; D006678:HIV / Q000472:pathogenicity / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008745:Methylation; D011533:Proviruses / Q000502:physiology; D012436:S-Adenosylmethionine / Q000378:metabolism; D013763:Tetrahydrofolates / Q000627:therapeutic use; D014779:Virus Replication; D014805:Vitamin B 12 / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D004279:DNA, Viral; D013763:Tetrahydrofolates; D012436:S-Adenosylmethionine; C019476:mecobalamin; D014805:Vitamin B 12; C005984:5-methyltetrahydrofolate